Sign In
NewsRadar

Press release centre

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.
   

Past Press Releases - Immunocore Ltd

July 16, 2015
Immunocore secures $320 million (£205 million) in Europe’s Largest Private Life Sciences Financing
Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today announced the completion of a US $320 million (GBP £205 million) private financing round. More

January 14, 2014
Immunocore to present at 32nd Annual JP Morgan Healthcare Conference and to provide an update on lea
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it will present at the 32nd annual JP Morgan Healthcare Conference on Thursday 16 January 2014 at 11:30 am (Pacific Time) at the Westin St Francis Hotel, San Francisco. More

January 8, 2014
Immunocore and MedImmune enter immunotherapy agreement to develop novel cancer therapies
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced that it has entered into an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology. More

November 14, 2013
Immunocore appoints Dr Jonathan Knowles as Chairman of the Board
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced the appointment of Dr Jonathan Knowles as the new executive Chairman of the Board of Directors with immediate effect. Dr Knowles succeeds Nicholas Cross who has been Chairman since the company was founded in 2008 and will remain on the Board as Deputy Chairman. More

October 3, 2013
Immunocore scoops OBN Best Biotech Dealmaker Award of 2013
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, has won the Best Biotech Dealmaker Award of 2013 at the OBN annual awards. More

September 24, 2013
Immunocore named one of Fierce 15 leading biotechs of 2013
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, has today been named by FierceBiotech as one of 2013’s Fierce 15 biotechs, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech’s eleventh annual Fierce 15 selection. More

July 9, 2013
Immunocore signs research and licensing agreement with GlaxoSmithKline
Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs called ImmTACs to treat cancer and viral disease, today announced it has entered into a partnership with GlaxoSmithKline (GSK) for multiple novel targets not addressable using antibody-based technologies. This is Immunocore’s second major partnership this year. More

May 2, 2013
Immunocore announces appointment of Eva-Lotta Allan to the Board
Immunocore Limited, the Oxford-based biotechnology company developing novel drugs to treat cancer and viral disease, today announced the appointment of Eva-Lotta Allan to the Board as Chief Business Officer. This is a new position, which has been created to strengthen the company’s management team as Immunocore continues to expand its operations. Ms Allan will join Immunocore on 7 May 2013. More

May 6, 2012
Revolutionary new cancer targeting technology described in Nature Medicine
A revolutionary cancer-targeting technology developed by researchers at Immunocore Limited has been described for the first time in the prestigious medical journal, Nature Medicine. The new reagents known as ImmTACs (Immune Mobilising mTCR against Cancer) mobilise T cells to kill cancer cells and overcome immune tolerance to cancer. More

October 5, 2010
Immunocore announces clinical trials of new treatment for advanced melanoma in UK and USA
(Oxford, UK, 5 October 2010) Researchers at Immunocore Limited today announced that IMCgp100, a targeted therapeutic for the treatment of advanced metastatic melanoma, has received regulatory and ethics approval and has opened enrolment for clinical trials in the UK and USA. IMCgp100 is the first clinical candidate originating from Immunocore’s innovative ImmTAC technology platform and a new treatment could benefit many thousands of patients diagnosed with skin cancer each year. More

February 1, 2010
Immunocore announces appointment of Dr Jonathan Knowles to the Board
Immunocore Limited, the Oxford-based pioneer of T cell receptor technology, announces the appointment of Dr Jonathan Knowles to the Board as a non-executive director with immediate effect. More

Data


26,837
Tech investments
From our Online Data Service
17,319
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Apr 2€6.0MOther Computers & Electronics
Apr 2€50.0MBiotechnology
Apr 2€0.7MMedical devices
Apr 2€0.9MWireless applications
Apr 2€100.0MContent management
Apr 1€416.0MOther Biotechnology & Healthcare

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.